Company

Ensho Therapeutics

Biotechnology Research 9 employees

Employees: 9
Contacts: 3
Emails: 3
Phones: 1

www.enshorx.com LinkedIn Crunchbase

Ensho Therapeutics Overview

Website: www.enshorx.com
Industry: Biotechnology Research
Employees: 9
Founded: 2024
Funding: 5.0M
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)

Keywords

Chuo-ku

About Ensho Therapeutics

Ensho Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company focused on developing breakthrough oral therapies for patients with inflammatory diseases. The company’s initial focus is on a pipeline of oral, selective small molecule inhibitors of lymphocyte homing integrin α4β7 for IBD, a mechanism already validated by a commercially available antibody. Ensho’s assets were acquired from EA Pharma Co., Ltd., a subsidiary of Eisai Co., Ltd., that is focused on gastrointestinal disease. Ensho is preparing to initiate a Phase 2 clinical program in UC with NSHO-101, the lead asset in the company’s pipeline.

Ensho Therapeutics Contact Details

People in AeroLeads: 4
With contact data: 3
Email contacts: 3; 75.0% coverage
Phone contacts: 1; 25.0% coverage

Ensho Therapeutics Org Chart

Sample employees and titles

Name	Title	Location	Contact
Matthew Mckevitt	Clinical Research	Seattle, Washington, United States	View
Danielle Fry	Chief Legal Officer & Chief Operating Officer at Ensho Therapeutics	New York City Metropolitan Area, United States	Email Phone
Matthew Warr	SVP, Research & Head of Biology at Ensho Therapeutics	United States	Email
Andy Whitney, Phd	Chief Scientific Officer at Ensho Therapeutics	Mercer Island, Washington, United States	Email